These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 2245168)
1. Pharmacokinetic studies with the antifolate C2-desamino-C2-methyl-N10-propargyl-2'-trifluoromethyl-5,8-dideazafolic acid (CB3988) in mice and rats using in vivo 19F-NMR spectroscopy. Newell DR; Maxwell RJ; Bisset GM; Jodrell DI; Griffiths JR Br J Cancer; 1990 Nov; 62(5):766-72. PubMed ID: 2245168 [TBL] [Abstract][Full Text] [Related]
2. 19F nuclear magnetic resonance imaging of drug distribution in vivo: the disposition of an antifolate anticancer drug in mice. Maxwell RJ; Frenkiel TA; Newell DR; Bauer C; Griffiths JR Magn Reson Med; 1991 Jan; 17(1):189-96. PubMed ID: 2067393 [TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of the quinazoline antifolate ICI D 1694 in mice and rats. Jodrell DI; Newell DR; Gibson W; Hughes LR; Calvert AH Cancer Chemother Pharmacol; 1991; 28(5):331-8. PubMed ID: 1914075 [TBL] [Abstract][Full Text] [Related]
5. In vivo and ex vivo magnetic resonance spectroscopy as applied to pharmacokinetic studies with anticancer agents: a review. Newell DR; Maxwell RJ; Golding BT NMR Biomed; 1992; 5(5):273-8. PubMed ID: 1449968 [TBL] [Abstract][Full Text] [Related]
7. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo. Jackman AL; Taylor GA; O'Connor BM; Bishop JA; Moran RG; Calvert AH Cancer Res; 1990 Sep; 50(17):5212-8. PubMed ID: 2386929 [TBL] [Abstract][Full Text] [Related]
8. The in vivo metabolic stability of dipeptide analogues of the quinazoline antifolate, ICI 198583, in mice. Jodrell DI; Gibson W; Bisset GM; Boyle FT; Judson IR; Jackman AL Biochem Pharmacol; 1993 Dec; 46(12):2229-34. PubMed ID: 8274156 [TBL] [Abstract][Full Text] [Related]
9. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism. Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737 [TBL] [Abstract][Full Text] [Related]
10. Folate-based inhibitors of thymidylate synthase: synthesis and antitumor activity of gamma-linked sterically hindered dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583). Bavetsias V; Jackman AL; Marriott JH; Kimbell R; Gibson W; Boyle FT; Bisset GM J Med Chem; 1997 May; 40(10):1495-510. PubMed ID: 9154971 [TBL] [Abstract][Full Text] [Related]
11. Folate analogues. 35. Synthesis and biological evaluation of 1-deaza, 3-deaza, and bridge-elongated analogues of N10-propargyl-5,8-dideazafolic acid. Li SW; Nair MG; Edwards DM; Kisliuk RL; Gaumont Y; Dev IK; Duch DS; Humphreys J; Smith GK; Ferone R J Med Chem; 1991 Sep; 34(9):2746-54. PubMed ID: 1895294 [TBL] [Abstract][Full Text] [Related]
12. Folate analogues. 32. Synthesis and biological evaluation of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid and related compounds. Patil SD; Jones C; Nair MG; Galivan J; Maley F; Kisliuk RL; Gaumont Y; Duch D; Ferone R J Med Chem; 1989 Jun; 32(6):1284-9. PubMed ID: 2542557 [TBL] [Abstract][Full Text] [Related]
13. Thymidylate synthase: a target for anticancer drug design. Harrap KR; Jackman AL; Newell DR; Taylor GA; Hughes LR; Calvert AH Adv Enzyme Regul; 1989; 29():161-79. PubMed ID: 2633608 [TBL] [Abstract][Full Text] [Related]
14. Dose dependent retention and polyglutamation of N10-propargyl-5,8-dideazafolic acid (CB 3717) in the tumour-bearing mouse. Manteuffel-Cymborowska M; Kaminska B; Grzelakowska-Sztabert B Anticancer Res; 1988; 8(4):791-6. PubMed ID: 3178167 [TBL] [Abstract][Full Text] [Related]
15. Polyglutamation of the antifolate anticancer drug N10-propargyl-5,8-dideazafolic acid (CB 3717) in the mouse. Manteuffel-Cymborowska M; Sikora E; Grzelakowska-Sztabert B Anticancer Res; 1986; 6(4):807-12. PubMed ID: 2875688 [TBL] [Abstract][Full Text] [Related]
17. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors. Jansen G; Schornagel JH; Westerhof GR; Rijksen G; Newell DR; Jackman AL Cancer Res; 1990 Dec; 50(23):7544-8. PubMed ID: 2253202 [TBL] [Abstract][Full Text] [Related]
18. Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid: a novel folate-based thymidylate synthase inhibitor. O'Connor BM; Jackman AL; Crossley PH; Freemantle SE; Lunec J; Calvert AH Cancer Res; 1992 Mar; 52(5):1137-43. PubMed ID: 1737372 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717) in the mouse. Newell DR; Alison DL; Calvert AH; Harrap KR; Jarman M; Jones TR; Manteuffel-Cymborowska M; O'Connor P Cancer Treat Rep; 1986 Aug; 70(8):971-9. PubMed ID: 3731153 [TBL] [Abstract][Full Text] [Related]